AUTHOR INDEX

P = proceedings

AARONS, L. *see* PITSIU, M.

ABAHUSAIN, A. *see* ALKHAWAJAH, A.

ABAHUSAIN, A., ALKHAWAJAH, A., ALGINDAN, Y., JAIN, S. & LARBI, E. The efficacy of topical ketoconazole in cutaneous leishmaniasis, 645P

ACTON, G., BROOM, C., HOWLAND, K. & MANCHEE, K. Effects of the dopaminergic D_2-receptor agonist ropinirole on posturally-induced changes in plasma catecholamines and haemodynamics, 619P

ACTON, G., BROOM, C. & MANCHEE, K. Effects of intravenous SK & F 95601, a novel H^+/K^+ ATPase inhibitor, on pentagastrin stimulated gastric acid output in healthy subjects, 609P

AELLIG, W. H. Nuclear magnetic resonance in clinical pharmacology and measurement of therapeutic response, 157

AFFRIME, M. *see* O'BRYNE, S.

AHMED, J. H., GODDEN, J., MEREDITH, P. A. & ELLIOTT, H. L. The pharmacokinetics and pharmacodynamics of (+)-verapamil in normotensive volunteers, 588P

AKHTAR, W. *see* VENABLES, T.

AL-AZAWIE, D. M., WEBB, A. J. KELLY, H. C. & DAVIES, B. E. A radioimmunoassay method for the novel gastrointestinal prokinetic agent, renzapride, in plasma, 618P

ALBERTI, K. G. M. M. *see* FERNER, R. E.

ALGINDAN, Y. *see* ABAHUSAIN, A.

ALGINDAN, Y. *see* ALKHAWAJAH, A.

ALI, A. *see* SLOVICK, D.

ALKHAWAJAH, A. *see* ABAHUSAIN, A.

ALKHAWAJAH, A., JAIN, S., ALGINDAN, Y., ABAHUSAIN, A. & LARBI, E. Subacute toxicity of pentavalent antimonials in rats, 623P

ALLAIN, P., MAURAS, Y., KRARI, N., DUCHIER, J., COURNOT, A. & LARCHEVEQUE, J. Plasma and urine aluminium concentrations in healthy subjects after administration of sucralfate, 391

ALLEN, A., ASGILL, C. C., PIERCE, D. M., UPWARD, J. W. & ZUSSMAN, B. D. Pharmacokinetics of ascending intravenous doses of granisetron, a novel 5-HT_3-receptor antagonist, 619

ALVAN, G., HELLEDAY, L., LINDHOLM, A., SANZ, E. & VILLEN, T. Diuretic effect and diuretic efficiency after intravenous dosage of frusemide, 215

ANDERSON, I. M., WILLIAMS, H., PARRY-BILLINGS, M. & NEWSHOLME, E. A. Dieting lowers plasma tryptophan in normal volunteers, 591

ANDERSON, T., ANDREN, K., CEDERBERY, C., LAGERSTROM, P. O., LUNDBORG, P. & SKANBERG, I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects, 557P

ANDREN, K. *see* ANDERSON, T.

ANGEL, M. E. *see* HAITAS, B.

ANGELBERGER, P. *see* VIRGOLINI, I.

ARNOLD, J. D., FORGACS, I. C., HUTCHISON, D. C. S., COSTELLO, J. & SWIFT, C. G. Effect of the benzodiazepine antagonist flumazenil on diazepam-induced respiratory depression during endoscopy, 593

ASGILL, C. C. *see* ALLEN, A.

ATKINSON, H. C. *see* ROBSON, R. A.

AVENANT, J. C. *see* MEYER, E. C.

BABA, T., MURABAYASHI, S., TOMIYAMA, T. & TAKEBE, K. The pharmacokinetics of enalapril in patients with compensated liver cirrhosis, 766

BAINBRIDGE, A., MACFADYEN, R. J., HOWIE, C. A., LEES, K. R. & REID, J. L. Ramipril and felodipine: an acute interaction study in normal volunteers, 628P

BAKES, A., BRADSHAW, C. M. & SZABADI, E. Diminished pupillary light reflex in anxiety disorder, 590P

BALFOUR, D. J. K. *see* LANG, C. C.

BAMMEL, A., HALABI, A., DIES, R. & KIRCH, W. Elimination and antihypertensive effect of anipamil in patients with normal and impaired renal function, 627P

BANNWARTH, B. *see* KESSLER, M.

BARAKA, O. Z., TRUMAN, C. A., FORD, J. M. & ROBERTS, C. J. C. The effect of propranolol on paracetamol metabolism in man, 261

BARDHAN, K. D. *see* ENGLAND, S.

BARENDREGT, J. N. M., VAN PEER, A., VAN DER HOEVEN, J. G., VAN OENE, J. C. & TJANDRA, Y. I. Ketanserin pharmacokinetics in patients with renal failure, 715

BARIN, E. S., WONG, C. K. Y., ELSTOB, J. E., DAVIES, D. W. & NATHAN, A. W. An acute study of the electrophysiological and haemodynamic effects of intravenous UK-52,046, a novel α_1-adrenoceptor antagonist, 359

BARKER, N. P. *see* JAMES, M. A.

BARNES, P. J. *see* NIX, A.

BARROW, S. E. *see* RITTER, J. M.

BARRY, M. *see* FEELY, J.

BASILISCO, G., CAMBONI, M. G., BOZZANI, A., MOLGORA, M. & BIANCHI, P. A. Single doses of ritodrine delay orocaecal transit in patients with irritable bowel syndrome, 355

BASTAIN, W. *see* JAMES, M. A.

BATEMAN, D. N. & RASHID, M. U. Gastric emptying, salivary flow and pulse rate responses to atropine in healthy young and elderly volunteers, 603P

BAUMANN, R. J. *see* ROBBINS, D. K.

BEARN, J. A., FAIRHALL, K. M., ROBINSON, I. C. A. F., LIGHTMAN, S. A. & CHECKLEY, S. A. A novel neuroendocrine test of central oestrogen receptor status in normal, puerperal and anorexic women, 604P

BEASTALL, G. H. *see* LARKIN, J. G.
BEGG, E. J. *see* ROBSON, R. A.
BELLISSANT, E. *see* THUILLEZ, C.
BELZ, G. G., BREITHAUPT, K., ERB, K. A. & WOLF, G. K. Non-invasive assessment of stroke volume in clinical pharmacology, 640P
BENJAMIN, N. & WEBB, D. J. The effect of local converting enzyme inhibition on the dilator response to substance P in the human forearm, 774
BENJAMIN, N. *see* RITTER, J. M.
BENNETT, P. N., HUMPHRIES, S. J., OSBORNE, J. P., CLARKE, A. K. & TAYLOR, A. Use of sodium aurothiomalate during lactation, 777
BENNETT, T. *see* RAHMAN, M. A.
BENZONI, D., BOUVIER, E., GALLET, M. & SASSARD, J. Ischaemia-induced stimulation of prostacyclin release: an *in vivo* marker of atherosclerosis, 638P
BERNAREGGI, A., DANESE, A., BUNIVA, B. G. & ROWLAND, M. Pharmacokinetics of individual components of teicoplanin in man, 612P
BERRY, J. L. *see* LONGMORE, J.
BERTINO JR, J. S. *see* CORSI, C. M.
BESAG, F. M. *see* BRODIE, M. J.
BETTERIDGE, D. J. *see* JAY, R. H.
BIANCHI, P. A. *see* BASILISCO, G.
BIEMOND, I., CROBACH, L. F. S. J., JANSEN, J. B. M. J. & LAMERS, C. B. H. W. Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers, 465
BIOLA MABADEJE, A. F. *see* SPIERS, C. J.
BIPPI, H. & FROLICH, J. C. Effects of acetylsalicylic acid and paracetamol alone and in combination on prostanoid synthesis in man, 305
BLASCHKE, T. F. *see* FORD, G. A.
BLOUIN, R. A. *see* GUTTENDORF, R. J.
BLYCHERT, E., WINGSTRAND, K., EDGAR, B. & LIDMAN, K. Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets, 39
BOCHNER, F. *see* SOMOGYI, A.
BOGER, R. S. *see* GRIFFITHS, A. N.
BOOBIS, A. R., SESARDIC, D., PASANEN, M., PELKONEN, O., SEGURA, J. & DAVIES, D. S. Tissue selective expression and inducibility of members of the cytochrome P4501A family in man, 603P
BOOBIS, A. R. *see* SESARDIC, D.
BOOBIS, A. R. *see* SPIERS, C. J.
BOONAMRUNG, S. *see* ROCHE, R. J.
BOUDOULAS, H. *see* PATEL, I. H.
BOULET, L. P., LACOURCIERE, Y., MILOT, J. & LAMPRON, N. Comparative effects of dilevalol and atenolol on lung function and airway response to methacholine in hypertensive subjects, 725
BOUVIER, E. *see* BENZONI, D.
BOVERS, J. *see* WILKENS, J. H.
BOWES, S. G. *see* HUGHES, J. R.
BOYD, G. *see* MILROY, R.
BOZZANI, A. *see* BASILISCO, G.
BRADSHAW, C. M. *see* BAKES, A.
BRADSHAW, C. M. *see* LONGMORE, J.
BRAYDEN, D. J. & CUTHBERT, A. W. A novel method for culturing sweat gland epithelia: comparison of normal and cystic fibrosis tissues, 235
BRAYDEN, D. J. *see* CUTHBERT, A. W.
BRECKENRIDGE, A. M. *see* COLEMAN, M. D.
BRECKENRIDGE, A. M. *see* HELSBY, N. A.
BRECKENRIDGE, A. M. *see* WINSTANLEY, P. A.
BREIMER, D. D. *see* DE BOER, A.
BREIMER, D. D. *see* SCHELLENS, J. H. M.
BREIMER, D. D. *see* SOONS, P. A.
BREIMER, D. D. *see* VAN HALL, M.
BREITHAUPT, K. *see* BELZ, G. G.
BRENDEL, E. *see* DE MEY, C.
BRITTO, M. *see* GUTTENDORF, R. J.
BRODIE, M. J., LARKIN, J. G., COX, A. & BESAG, F. M. A double-blind, crossover, placebo-controlled trial of adjuvant nifedipine in refractory epilepsy, 592P
BRODIE, M. J. *see* LARKIN, J. G.
BROOM, C. *see* ACTON, G.
BROSEN, K., DAVIDSEN, F. & GRAM, L. F. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man, 248
BRODEN, K. *see* DUE NIELSEN, M.
BROWN, M. J. *see* SHAWKET, S.
BRUNE, K. *see* SCHNEIDER, H. Th.
BRUNEL, P., LECAILLON, J. B., GUYENE, T. T., IMHOF, P. & MENARD, M. F. Influence of acetylator status on the haemodynamic effects and pharmacokinetics of cadralazine in healthy subjects, 503
BULLMAN, J. N. *see* GILL, T. S.
BUNIVA, B. G. *see* BERNAREGGI, A.
BURM, A. G. L. *see* TH. VEERING, B.
BURNS, D. E. *see* MCVEIGH, G. E.
BURNS, J. M. A. *see* GEMMILL, J. D.

CAMBONI, M. G. *see* BASILISCO, G.
CAMPBELL, I. *see* KRSKA, J.
CAMPBELL, L. M. *see* VENABLES, T.
CAPRON, A. *see* MARQUETTE, C. H.
CARABINE, U. A. *see* WRIGHT, P. M. C.
CARLYLE, D. *see* MILROY, R.
CARSON, N. *see* O'BRYNE, S.
CARTER, R. *see* MILROY, R.
CARTLIDGE, P. H. T. *see* CARTWRIGHT, R. G.
CARTWRIGHT, R. G., CARTLIDGE, P. H. T., RUTTER, N., MELIA, C. D. & DAVIES, S. S. Transdermal delivery of theophylline to premature infants using a hydrogel disc system, 533
CEDERBERY, C. *see* ANDERSON, T.
CH. MULLER *see* VIRGOLINI, I.
CHAN, G. T. C. *see* KUMANA, C. R.
CHAN, T. K. P. *see* KUMANA, C. R.
CHANG, S. L. *see* ROBBINS, D. K.
CHANNER, K. S. *see* JAMES, M. A.
CHAPTER, M. K. *see* THOMAS, M.
CHAVINIE, J. *see* PONS, G.
CHECKLEY, S. A. *see* BEARN, J. A.
CHU, P. I. *see* CURRY, S. H.
CHUNG, K. F. *see* NIX, A.
CLARK, R. A. *see* LIPWORTH, B. J.
CLARKE, A. K. *see* BENNETT, P. N.
COHEN, A. F. *see* DE BOER, A.
COHEN, A. F. *see* KROON, C.
COHEN, A. F. *see* SOONS, P. A.
COHEN, A. F. *see* VAN HALL, M.

COHN, J. N. *see* McVEIGH, G. E.
COLEMAN, J. W. *see* WINSTANLEY, P. A.
COLEMAN, M. D., HOAKSEY, P. E., BRECKENRIDGE, A. M. & PARK, B. K. Inhibition of dapsone-induced methaemaglobinaemia in the isolated perfused rat liver, 625P
COLEMAN, M. D. *see* RILEY, R. J.
COLEMAN, M. D. *see* TINGLE, M. D.
COPELAND, S. *see* PASSMORE, A. P.
COPPACK, S. W., LANT, A. F., McINTOSH, C. S. & RODGERS, A. V. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus, 673
CORSI, C. M., NAFZIGER, A. N., PIEPER, J. A. & BERTINO JR, J. S. Lack of effect of atenolol and nadolol on the metabolism of theophylline, 265
COSTELLO, J. *see* ARNOLD, J. D.
COULSON, R. R. *see* MACLEAN, D.
COURNOT, A. *see* ALLAIN, P.
COUTIE, W. J. R. *see* LANG, C. C.
COWEN, P. J. *see* SHARPLEY, A. L.
COX, A. *see* BRODIE, M. J.
CRICHTON, W. *see* WEBSTER, J.
CRIDLAND, J. S. The value of therapeutic drug monitoring, 278
CROBACH, L. F. S. J. *see* BIEMOND, I.
CROSS, N. *see* ROBERTSON, D. R. C.
CURRY, S. H., STACPOOLE, P. W., LORENZ, A., HENDERSON, G., MARS, D., CHU, P. I. & LIMACHER, M. Dichloroacetic acid: pharmacodynamics and pharmacokinetics, 622P
CUTHBERT, A. W., BRAYDEN, D. J., DUNNE, A., SMYTH, R. L. & WALLWORK J. Altered sensitivity to amiloride in cystic fibrosis. Observations using cultured sweat glands, 227
CUTHBERT, A. W. *see* BRAYDEN, D. J.

DAHLQVIST, R. *see* LINDHOLM, A.
DALY, M. J. *see* ENGLAND, S.
DANESE, A. *see* BERNAREGGI, A.
DANESHMEND, T. Diseases and drugs but not food decrease ketoconazole 'bioavailability', 783
DANIELSON, B. G. *see* SALMONSON, T.
DAVIDSEN, F. *see* BROSEN, K.
DAVIES, B. E. *see* AL-AZAWIE, D. M.
DAVIES, B. E. *see* GILL, T. S.
DAVIES, D. S. *see* BOOBIS, A. R.
DAVIES, D. S. *see* SESARDIC, D.
DAVIES, D. S. *see* SPIERS, C. J.
DAVIES, D. W. *see* BARIN, E. S.
DAVIES, S. S. *see* CARTWRIGHT, R. G.
DE BOER, A., KROON, J. M., KROON, C., VAN VLIET, A., BREIMER, D. D., DONOGHUE, S. & COHEN, A. F. Synergistic effect of a new thromboxane antagonist (GR32191) and heparin on bleeding time in healthy male volunteers, 599P
DE BOER, A. *see* KROON, C.
DE BOER, A. *see* SOONS, P. A.
DE LA TORRE, R. *see* SESARDIC, D.
DE MEY, C., BRENDEL, E. & ENTERLING, D. Carvedilol increases the systemic bioavailability of oral digoxin, 486
DE MAY, C. *see* HOWLAND, K.
DE SALAMANCA, R. E. *see* MUNOZ, J. J.
DESCHE, P. *see* SLOVICK, D.
DESHMUKH, A. A. *see* HUGHES, J. R.
DEWHURST, A. G. *see* OLIVER, R. M.
DHILLON, D. P. *see* LIPWORTH, B. J.
DICKERSON, J. E. C. *see* SHAWKET, S.
DICKSON, A. C. *see* JAY, R. H.
DIES, R. *see* BAMMEL, A.
DIETZEL, K. *see* SCHNEIDER, H. Th.
DILLON, S. *see* JAVLE, H.
DIAZ-OBREGON, C. *see* MUNOZ, J. J.
DISCI, L. J., GOOD, S. M., HALL, R. W. & ILETT, K. F. Excretion of diazepam and its metabolites in human milk during withdrawal from high dose diazepam and oxazepam, 123
DIXON, M. S. *see* THOMAS, P.
DOBBS, R. J. *see* HUGHES, J. R.
DOBBS, S. M. *see* HUGHES, J. R.
DOBSON, A. *see* HENRY, D.
DOKTOR, H. S. *see* RITTER, J. M.
DOLLERY, C. T. *see* TAYLOR, I. K.
DONNELLY, R., MEREDITH, P. A., ELLIOTT, H. L. & REID, J. L. The description and prediction of response to antihypertensive treatment with enalapril, 611P
DONOGHUE, S. *see* DE BOER, A.
DONOHOE, J. *see* VANDENBURG, M. J.
DOSSING, M. *see* SONNE, J.
DOUSSET, *see* KESSLER, M.
DOWNIE, G. *see* KRSKA, J.
DOYLE, G. D. *see* VANDENBURG, M. J.
DRAGANIC, B., HENRY, D., SMITH, A., WHYTE, I. & O'CONNELL, D. Optimal therapeutic range for serum lithium concentrations during maintenance therapy for bipolar affective disorders, 592P
DUCHIER, J. *see* ALLAIN, P.
DUE NIELSEN, M., BROSEN, K. & GRAM, L. F. A dose-effect study of the *in vivo* inhibitory effect of quinidine on sparteine oxidation in man, 299
DUFFIN, D. *see* JOHNSTON, G. D.
DUNDEE, J. W. & GHALY, R. G. Observations on the action of P6 acupuncture antiemesis, 601P
DUNDEE, J. W. & YANG, J. Acupressure prolongs the antiemetic action of P6 acupuncture, 644P
DUNN, F. G. *see* GIRBES, A. R. J.
DUNNE, A. *see* CUTHBERT, A. W.
DUPONT, A. G. *see* SCHOORS, D. F.
DUSCI, L. J. *see* HACKETT, L. P.

ECHIZEN, H., NAKURA, M., SAOTOME, T., MINOURA, S. & ISHIZAKI, T. Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers, 423
EDGAR, B. *see* BLYCHERT, E.
EDWARDS, G. *see* WINSTANLEY, P. A.
EGOROV, L. V. *see* YU. MARTSEVICH, S.
ELBORN, J. S., RILEY, M., STANFORD, C. F. & NICHOLLS, D. P. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure, 519
ELBORN, J. S. *see* RILEY, M.
ELDELBROEK, P. M. *see* KROON, C.
ELLIOTT, H. L. *see* AHMED, J. H.

ELLIOTT, H. L. *see* DONNELLY, R.
ELLIOTT, H. L. *see* MACPHEE, G. J. A.
ELSTOB, J. E. *see* BARIN, E. S.
EMMANUEL, M. *see* KAMALI, F.
ENGLAND, S., DALY, M. J., JACOB, S. & BARDHAN, K. D. Comparison of the inhibitory characteristics of cimetidine and omeprazole on human isolated parietal cells, 610P
ENTERLING, D. *see* DE MEY, C.
ERB, K. A. *see* BELZ, G. G.
ERIKSSON, S. *see* HASSELSTROM, J.

FABEL, H. *see* WILKENS, J. H.
FAIRHALL, K. M. *see* BEARN, J. A.
FEARS, R. *see* GIRBES, A. R. J.
FEE, J. P. H. *see* MCLOUGHLIN, C.
FEE, J. P. H. *see* WRIGHT, P. M. C.
FEELY, J. & GRIMM, T. Racial differences in drug protein binding, 634P
FEELY, J., HOLLAND, P. & BARRY, M. Genetic polymorphism in Ireland and influence of quinine tonic water on hydroxylation, 633P
FEELY, J. *see* O'CONNOR, P.
FEELY, *see* O'BRYNE, S.
FERNANDO, A. *see* SHARPLEY, A. L.
FERNER, R. E., ALBERTI, K. G. M. M. & RAWLINS, M. D. The acute effects of tolbutamide during a glucose clamp and after a mixed meal in patients with non-insulin dependent diabetes, 638P
FERNER, R. E., KAMALI, F. & RAWLINS, M. D. The effect of sulindac on dermal responses to bradykinin in normal subjects given an angiotensin converting enzyme inhibitor, 363
FERRES, J. *see* GIRBES, A. R. J.
FINKELSTEIN, S. M. *see* MCVEIGH, G. E.
FINNERTY, J. P., HOLGATE, S. T. & RIHOUX, J. P. The effect of 2 weeks treatment with cetirizine on bronchial reactivity to methacholine in asthma, 79
FITZSIMONS, T. J. *see* MACLEAN, D.
FLACHS, H. *see* PETRING, O. U.
FLEMING, J. S. *see* ROBERTSON, D. R. C.
FORD, G. A., HOFFMAN, B. B. & BLASCHKE, T. F. Effect of temazepam on blood pressure regulation in healthy elderly subjects, 61
FORD, J. M. *see* BARAKA, O. Z.
FORGACS, I. C. *see* ARNOLD, J. D.
FORREST, G. *see* LARKIN, J. G.
FORSTER, J. K. *see* MACONOCHIE, J. G.
FOSTER, T. S. *see* GUTTENDORF, R. J.
FOURNIER, A. *see* SLOVICK, D.
FOWLER, G. *see* JAMIESON, M. J.
FOWLES, S. E., PIERCE, D. M., PRINCE, W. T. & THOW, J. C. Effect of food on the bioavailability and pharmacokinetics of penciclovir, a novel antiherpes agent, following oral administration of the pro-drug famiciclovir, 620P
FOX, Y. *see* VENABLES, T.
FRAMPTON, C. M. *see* ROBSON, R. A.
FRANCOUAL, CH. *see* PONS, G.
FROLICH, J. C. *see* BIPI, H.
FROLICH, J. C. *see* WILKENS, J. H.
FUKUDA, E. K. *see* PATEL, I. H.
FUKUSHIMA, Y. *see* KONDO, T.
FULLER, R. W. *see* TAYLOR, I. K.

GALLET, M. *see* BENZONI, D.
GARRIGUES, T. M., MARTIN, U., PLA-DELFINA, J. M. & PRESCOTT, L. F. Dose-dependent cefadroxil absorption and elimination, 602P
GAVEY, C. J., SMITH, J. T. L., NWOKOLO, C. U. & POUNDER, R. E. Clofibrate raises human 24 h intragastric acidity but does not affect plasma gastrin concentration, 473
GEMMILL, J. D., HOGG, K. J., BURNS, J. M. A. & RAE, A. P. Comparison of the pharmacokinetic properties of anistreplase and streptokinase in acute myocardial infarction, 597P
GEORGE, C. F. *see* ROBERTSON, D. R. C.
GEORGE, G., WYNNE, H. A. & WOODHOUSE, K. W. The effect of age upon induction of drug metabolising enzymes in human monocytes, 637P
GHALY, R. G. *see* DUNDEE, J. W.
GILL, T. S., BULLMAN, J. N., STANIFORTH, D. H. & DAVIES, B. E. The pharmacokinetic and haemodynamic effects of intravenous cromakalim in man, 617P
GIRBES, A. R. J., SMIT, A. J., MEIJER, S., REITSMA, W. D., DUNN, F. G., FEARS, R., FERRES, J., STANDING, R., GREENWOOD, H. C., PIERCE, D. & HILLIS, W. S. Lack of effect of lithium on the renal response to DA_1-dopamine receptor stimulation by fenoldopam in normal man, 413
GIUDICELLI, J. F. *see* THUILLEZ, C.
GIVEN, B. *see* O'BRYNE, S.
GLASSMAN, H. N. *see* GRIFFITHS, A. N.
GLOVER, D. R. *see* VANDENBURG, M. J.
GLOVER, J. *see* VLAVIANOS, P.
GODDEN, J. *see* AHMED, J. H.
GOKAL, R. *see* TOON, S.
GOOD, S. M. *see* DISCI, L. J.
GRAHAM, B. R. *see* TOMLINSON, B.
GRAHAM, I. *see* O'CONNOR, P.
GRAM, L. F. *see* BROSEN, K.
GRAM, L. F. *see* DUE NIELSEN, M.
GREENWOOD, H. C. *see* GIRBES, A. R. J.
GRIFFITHS, A. N., NEUTEL, J. M., GLASSMAN, H. N., BOGER, R. S., WEBER, M. A. & LUTHER, R. R. The hypotensive effect of increasing doses of enalkrein, a dipeptide renin inhibitor, compared with enalprilat in hypertensive patients, 614P
GRIMM, T. *see* FEELY, J.
GROOM, P. *see* VENABLES, T.
GRUNWALD, J. Garlic and cardiovascular risk factors, 583
GUTTENDORF, R. J., BRITTO, M., BLOUIN, R. A., FOSTER, T. S., JOHN, W., PITTMAN, K. A. & WEDLUND, P. J. Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism, 373
GUY, S. & SILKE, B. Assessment of cardiac performance during pharmacodynamic intervention using cardiac power output calculators, 608P
GUY, S. *see* SILKE, B.
GUYENE, T. T. *see* BRUNEL, P.

HACKETT, L. P., WOJNAR-HORTON, R. E., DUSCI, L. J., ILETT, K. F. & ROBERTS, M. J. Excretion of sotalol in breast milk, 277

HAINSWORTH, R. *see* WAHBHA, M. M. A. E.
HAITAS, B., MEYER, T. E., ANGEL, M. E. & REEF, E. Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure, 366
HALABI, A. *see* BAMMEL, A.
HALL, R. W. *see* DISCI, L. J.
HALL, P. *see* HENRY, D.
HAMBERG, O. *see* SONNE, J.
HARRIGAN, J. R., LEES, K. R. & MEREDITH, P. A. Age and the physiologically realistic characterisation of benazeprilat pharmacokinetics, 589P
HARRON, D. W. G. *see* McKAIGUE, J. P.
HARRY, J. D. *see* JAMES, M. A.
HASSELSTROM, J., ERIKSSON, S., PERSSON, A., RANE, A., SVENSSON, J. O. & SAWE, J. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis, 289
HAZLEMAN, B. *see* SHAWKET, S.
HELLEDAY, L. *see* ALVAN, G.
HELLER, S. R. *see* KERR, D.
HELSBY, N. A., WARD, S. A., HOWELLS, R. E. & BRECKENRIDGE, A. M. *In vitro* metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme, 623P
HENDERSON, G. *see* CURRY, S. H.
HENRICSSON, S. *see* LINDHOLM, A.
HENRY, D., THIRKETTLE, C., DOBSON, A. & HALL, P. NSAIDs and risk of peptic ulcer complications: the importance of age and a number of other factors, 606P
HENRY, D. *see* DRAGANIC, B.
HENRY, J. A. *see* MINTON, N. A.
HERMAN, R. J. *see* VERBEECK, R. K.
HEWSON, D. *see* SOMOGYI, A.
HIFT, R., SOHNIUS, U. & MEISSNER, P. N. Safety of vancomycin in acute porphyria, 273
HIGGINSON, J. *see* ROBERTSON, D. R. C.
HILLIS, W. S. *see* GIRBES, A. R. J.
HINE, F. L. *see* MARLOW, H. F.
HIRANO, T. *see* KONDO, T.
HOAKSEY, P. E. *see* COLEMAN, M. D.
HOFFMAN, B. B. *see* FORD, G. A.
HOGG, K. J. *see* GEMMILL, J. D.
HOLGATE, S. T. *see* FINNERTY, J. P.
HOLLAND, P. *see* FEELY, J.
HONEYWELL, R. *see* OLIVER, R. M.
HOPMAN, W. P. M., ROSENBUSCH, G., JANSEN, J. B. M. J. & LAMBERS, C. B. H. W. Effect of increasing oral doses of loperamide on gallbladder motility in man, 55
HORAI, Y., TAGA, J., ISHIZAKI, T. & ISHIKAWA, K. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese polulation, 111
HOWELLS, R. E. *see* HELSBY, N. A.
HOWES, L. G., ROWES, P. R., KRUM, H. & LOUIS, W. J. The effects of a single dose of dilevalol on [^{3}H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations, 281
HOWIE, C. A. *see* BAINBRIDGE, A.
HOWIE, C. A. *see* MacPHEE, G. J. A.
HOWLAND, K., DE MAY, C. & MEINEKE, I. Sequence effects and treatment × period interaction in two-period crossover studies, 626P
HOWLAND, K. *see* ACTON, G.
HUGHES, J. R., BOWES, S. G., LEEMAN, A. L., O'NEILL, C. J. A., DESHMUKH, A. A., NICHOLSON, P. W., DOBBS, S. M. & DOBBS, R. J. Parkinsonian abnormality in foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?, 179
HUMPHREYS, F. & SHUSTER, S. The effect of indomethacin on the kinetics of histamine, 48/80 and antigen wealing, 195
HUMPHRIES, S. J. *see* BENNETT, P. N.
HUTCHISON, D. C. S. *see* ARNOLD, J. D.

ILETT, K. F. *see* DISCI, L. J.
ILETT, K. F. *see* HACKETT, L. P.
IMHOFF, P. *see* BRUNEL, P.
IRVINE, N. *see* MACLEAN, D.
ISHIKAWA, K. *see* HORAI, Y.
ISHIZAKI, T. *see* ECHIZEN, H.
ISHIZAKI, T. *see* HORAI, Y.

JACKSON, N. C. *see* SILKE, B.
JACOB, S. *see* ENGLAND, S.
JAIN, S. *see* ABAHUSAIN, A.
JAIN, S. *see* ALKHAWAJAH, A.
JAMES, M. A., PAPOUCHADO, M., CHANNER, K. S., JONES, J. V., MARLOW, H. F., BASTAIN, W., BARKER, N. P., HARRY, J. D. & WARDELWORTH, A. G. The effect of oral dosing of xamoterol on systolic time intervals in man and xamoterol plasma concentrations in heart failure patients, 447
JAMIESON, M. J., WEBSTER, J., FOWLER, G., PETRIE, J. C., NUTTALL, A., SMITH, S., RAWLES, J. & SMITH, F. W. A comparison of the chronic effects of oral xamoterol and enalapril on blood pressure and renal function in mild to moderate heart failure 641P
JAMIESON, M. *see* WEBSTER, J.
JANSEN, J. B. M. J. *see* BIEMOND, I.
JANSEN, J. B. M. J. *see* HOPMAN, W. P. M.
JANSEN, J. B. M. J. *see* JEBBINK, M. C. W.
JAPPY, B. *see* KRSKA, J.
JAVLE, H., KEANEY, N. P., SMY, J. R., LEE, M. & DILLON, S. The effect of late restimulation with pilocarpine on the output of lactate in sweat in volunteers, 636P
JAY, R. H., DICKSON, A. C. & BETTERIDGE, D. J. Effects of aspirin upon the flushing reaction induced by niceritrol, 120
JAZBIK, W. *see* SOARES DE MOURA, R.
JEBBBINK, M. C. W., JANSEN, J. B. M. J., MASCLEE, A. A. M. & LAMERS, C. B. H. W. Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man, 770
JEFFERS, T. A. *see* WEBSTER, J.
JOHANSEN, T. *see* MOLLER, B.
JOHN, W. *see* GUTTENDORF, R. J.
JOHNSTON, A. *see* SALEH, S.
JOHNSTON, G. D., WILSON, R. E. A., McDERMOTT,

B. J. & DUFFIN, D. A long term comparison of the antihypertensive and metabolic effects of low and conventional dose cyclopenthiazide, 586P
JOHNSTON, G. D. *see* MCVEIGH, G. E.
JOHNSTON, G. D. *see* PASSMORE, A. P.
JONES, J. V. *see* JAMES, M. A.
JOSEPH, M. *see* MARQUETTE, C. H.

KAMALI, F., EMMANUEL, M. & RAWLINS, M. D. A dose-response study of noberastine, a new antihistamine, 607P
KAMALI, F. *see* FERNER, R. E.
KANEKO, S. *see* KONDO, T.
KATZ, L. *see* O'BRYNE, S.
KEANEY, N. P. *see* JAVLE, H.
KEERY, R. J. *see* THOMAS, M.
KELLY, H. C. *see* AL-AZAWIE, D. M.
KELLY, J. G. *see* VANDENBURG, M. J.
KENSINGTON, J. E. *see* THOMAS, M.
KERR, D., MACDONALD, I. A., HELLER, S. R. & TATTERSALL, R. B. β-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects, 685
KESSLER, M., NETTER, P., RENOULT, E., TRECHOT, P., DOUSSET, B. & BANNWARTH, B. Lack of effect of spiramycin on cyclosporin pharmacokinetics, 370
KHAN, M. M. *see* RILEY, M.
KHOO, K. C. *see* WILLS, R. J.
KIRCH, W. *see* BAMMEL, A.
KITTERINGHAM, N. R. *see* RILEY, R. J.
KOFI-EKUE, J. M. *see* WINSTANLEY, P. A.
KONDO, T., OTANI, K., HIRANO, T., KANEKO, S. & FUKUSHIMA, Y. The effects of phenytoin and carbamazepine on serum concentrations of monounsaturated metabolites of valproic acid, 116
KOU, M. *see* KUMANA, C. R.
KRARI, N. *see* ALLAIN, P.
KROON, C., DE BOER, A., VAN DER MEER, F. J. M., ELDELBROEK, P. M., SCHOEMAKER, H. C. & COHEN, A. F. Interactions between single dose acenocoumarol and cimetidine or pentobarbitone: validation of a single dose model to predict interactions in steady state, 643P
KROON, C. *see* DE BOER, A.
KROON, J. M. *see* DE BOER, A.
KRSKA, J., CAMPBELL, I., JAPPY, B., DOWNIE, G., SMITH, M., WILLIAMS, A. & PETRIE, J. C. Hospital drug formulations—feed-back information for prescribers, 630P
KRUM, H. *see* HOWES, L. G.
KUHN, R. *see* ROBBINS, D. K.
KUMANA, C. R., CHAN, G. T. C., YU, Y. L., LAUDER, I. J., CHAN, T. K. P. & KOU, M. Investigation of intravascular haemolysis during treatment of acute stroke with intravenous glycerol, 347

LACOURCIERE, Y. *see* BOULET, L. P.
LAGERSTROM, P. O. *see* ANDERSON, T.
LAHER, M. S. *see* VANDENBURG, M. J.
LAMERS, C. B. H. W. *see* BIEMOND, I.
LAMERS, C. B. H. W. *see* HOPMAN, W. P. M.
LAMERS, C. B. H. W. *see* JEBBINK, M. C. W.
LAMPRON, N. *see* BOULET, L. P.
LANG, C. C., RAHMAN, A. R., COUTIE, W. J. R., BALFOUR, D. J. K. & STRUTHERS, A. D. Atrial natriuretic factor inhibits metoclopramide-stimulated aldosterone release in humans, 606P
LANT, A. F. *see* COPPACK, S. W.
LARBI, E. *see* ABAHUSAIN, A.
LARBI, E. *see* ALKHAWAJAH, A.
LARCHEVEQUE, J. *see* ALLAIN, P.
LARKIN, J. G., MCKEE, P. J., FORREST, G., BEASTALL, G. H., PARK, B. K., LOWRIE, J. I., LLOYD, P. & BRODIE, M. J. Evidence of lack of auto- and hetero-induction with the novel anticonvulsant oxcarbazepine in health volunteers, 643P
LARKIN, J. G. *see* BRODIE, M. J.
LASALLE, P. *see* MARQUETTE, C. H.
LAUDER, I. J. *see* KUMANA, C. R.
LECAILLON, J. B. *see* BRUNEL, P.
LEE, E. J. D. *see* WANWIMOLRUK, S.
LEE, M. *see* JAVLE, H.
LEEMAN, A. L. *see* HUGHES, J. R.
LEES, K. R. *see* BAINBRIDGE, A.
LEES, K. R. *see* HARRIGAN, J. R.
LEIER, C. V. *see* PATEL, I. H.
LENNON, P. *see* THAM, T. C. K.
LEVY, R. H. *see* ROBBINS, D. K.
LEWIS, R. *see* MACLEAN, D.
LIDMAN, K. *see* BLYCHERT, E.
LIGHTMAN, S. A. *see* BEARN, J. A.
LIMACHER, M. *see* CURRY, S. H.
LINDHOLM, A., HENRICSSON, S. & DAHLQVIST, R. The effect of food and bile acid administration on the relative bioavailability of cyclosporin, 541
LINDHOLM, A. *see* ALVAN, G.
LIPWORTH, B. J., CLARK, R. A., DHILLON, D. P. & MCDEVITT, D. G. Evaluation of β-adrenoceptor response in normal airways using the forced oscillation technique, 613P
LIPWORTH, B. J., TREGASKIS, B. F. & MCDEVITT, D. G. β_2-adrenoceptor responses to salbutamol are unaltered in the elderly, 137P
LIS, Y. *see* TURNBULL, A. G.
LLOYD, P. *see* LARKIN, J. G.
LOEWEN, G. R. *see* VERBEECK, R. K.
LOFT, S. *see* SONNE, J.
LONGMORE, J., BERRY, J. L., SZABADI, E. & BRADSHAW, C. M. Comparison of two formulations of disopyramide on cholinergic functions in human volunteers, 633P
LOOAREESUWAN, S. *see* ROCHE, R. J.
LORENZ, A. *see* CURRY, S. H.
LOUIS, W. J. *see* HOWES, L. G.
LOWRIE, J. I. *see* LARKIN, J. G.
LUMLEY, P. *see* THOMAS, M.
LUNDBORG, P. *see* ANDERSON, T.
LUTHER, R. R. *see* GRIFFITHS, A. N.

MACDONALD, I. A. *see* KERR, D.
MACDONALD, J. I. *see* VERBEECK, R. K.
MACFADYEN, R. J. *see* BAINBRIDGE, A.

MacKay, E. M. *see* Vandenburg, M. J.
Macklin, B. S. *see* Robertson, D. R. C.
Maclean, D., Mitchell, E. T., Lewis, R., Irvine, N., McLay, J. S., McEwen, J., Coulson, R. R., Slater, N. D., Fitzsimons, T. J. & McDevitt, D. G. Comparison of once daily atenolol nitrendipine and their combination in mild to moderate essential hypertension, 455
MacLennan, B. A. *see* McKaigue, J. P.
MacPhee, G. J. A., Howie, C. A., Elliott, H. L. & Reid, J. L. Comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects, 596P
Maconochie, J. G. & Forster, J. K. The pharmacological effect of high dose inhaled salmeterol, 632P
Maggs, J. L. *see* Winstanley, P. A.
Manchee, K. *see* Acton, G.
Manson, L. M. *see* Prescott, L. F.
Mansy, S. *see* Venables, T.
Mant, T. G. K. *see* Ritter, J. M.
Marlow, H. F., Hine, F. L., Snow, H. M., Pouleur, H. & Rousseau, M. F. Relationship between positive inotropic responses and plasma concentrations of xamoterol in middle-aged and elderly patients, 511
Marlow, H. F. *see* James, M. A.
Marquette, C. H., Joseph, M., Tonnel, A. B., Vornig, H., Lasalle, P., Tsicopoulos, A. & Capron, A. The abnormal *in vitro* response to aspirin of platelets from aspirin-sensitive asthmatics is inhibited after inhalation of nedocromil sodium but not of sodium cromoglycate, 525
Mars, D. *see* Curry, S. H.
Martin, U. *see* Garrigues, T. M.
Masclee, A. A. M. *see* Jebbink, M. C. W.
Massart, D. L. *see* Schoors, D. F.
Matsuno, H., Uematsu, T. & Nakishima, M. The measurement of haloperidol and reduced haloperidol in hair as an index dosage history, 187
Mattison, P. *see* Prescott, L. F.
Mauras, Y. *see* Allain, P.
Mawer, G. E. *see* Wildin, J. D.
McClune, S. *see* Wright, P. M. C.
McDermott, B. J. *see* Johnston, G. D.
McDevitt, D. G. *see* Lipworth, B. J.
McDevitt, D. G. *see* Maclean, D.
McEwen, J. *see* Maclean, D.
McInnes, G. T. Therapeutic drug monitoring-an hypothesis still in need of testing, 133
McIntosh, C. S. *see* Coppack, S. W.
McKaigue, J. P., MacLennan, B. A. & Harron, D. W. G. The effects of xamoterol on tests of autonomic function in man, 631P
McKee, P. J. *see* Larkin, J. G.
McKinney, M. S. *see* McLoughlin, C.
McLay, J. S. *see* Maclean, D.
McLoughlin, C., Fee, J. P. H. & McKinney, M. S. Diclofenac sodium for day case arthoscopy, 600P
McVeigh, G. E., Burns, D. E., Johnston, G. D., Finkelstein, S. M. & Cohn, J. N. Reduced arterial vascular compliance as a marker for essential hypertension, 587P
Meijer, S. *see* Girbes, A. R. J.
Meineke, I. *see* Howland, K.
Meissner, P. N. *see* Hift, R.
Melia, C. D. *see* Cartwright, R. G.
Mernard, M. F. *see* Brunel, P.
Menzies, D. G. *see* Prescott, L. F.
Meredith, P. A. *see* Ahmed, J. H.
Meredith, P. A. *see* Donelly, R.
Meredith, P. A. *see* Harrigan, J. R.
Metelitsa, V. I. *see* Yu. Martsevich, S.
Meyer, E. C., Somers, De K., Schoeman, H. S. & Avenant, J. C. The effect of autonomic blockers on heart rate: a comparison between two ethnic groups, 254
Meyer, E. C. *see* Snyman, J. R.
Meyer, T. E. *see* Haitas, B.
Millington, L. *see* Wildin, J. D.
Milot, J. *see* Boulet, L. P.
Milroy, R., Carter, R., Carlyle, D. & Boyd, G. Clinical and pharmacological study of a novel controlled release preparation of salbutamol, 578
Minoura, S. *see* Echizen, H.
Minton, N. A., Henry, J. A., Rolls, L. J. & Smith, K. J. Prevention of drug absorption following simulated overdose of sustained-release theophylline, 605P
Mitchell, E. T. *see* Maclean, D.
Molgora, M. *see* Basilisco, G.
Moller, B., Vaag, A. & Johansen, T. Ouabain inhibition of the sodium-potassium pump: estimation of ED_{50} in different types of human leucocytes *in vitro*, 93
Molunto, P. *see* Roche, R. J.
Moore, J. *see* Wright, P. M. C.
Moran, C. *see* Pons, G.
Morin, D. *see* Sini, R.
Morrison, R. A. *see* Singhvi, S. M.
Muirhead, M. *see* Somogyi, A.
Mulyono, *see* Samigun
Munoz, J. J., De Salamanca, R. E., Diaz-Obergon, C. & Timoneda, F. L. The effect of clobazam on steady state plasma concentrations of carbamazepine and its metabolites, 763
Murabayashi, S. *see* Baba, T.
Murray, B. P. *see* Sesardic, D.
Murray, S. *see* Sesardic, D.
Murray, S. *see* Spiers, C. J.
Murray, S. *see* Taylor, I. K.
Musch, G. *sec* Schoors, D. F.

Nafziger, A. N. *see* Corsi, C. M.
Nakashima, M. *see* Matsuno, H.
Nakura, M. *see* Echizen, H.
Naqvi, N. *see* Venables, T.
Nathan, A. W. *see* Barin, E. S.
Netter, P. *see* Kessler, M.
Neutel, J. M. *see* Griffiths, A. N.
Newsholme, E. A. *see* Anderson, I. M.
Nichol, G. M. *see* Nix, A.
Nicholls, D. P. *see* Elborn, J. S.
Nicholls, D. P. *see* Riley, M.
Nicholson, P. W. *see* Hughes, J. R.
Nix, A., Nichol, G. M., Robson, A., Barnes, P. J. & Chung, K. F. Effect of formoterol, a long-lasting β_2-adrenoceptor agonist, against methacholine-induced bronchoconstriction, 321

NUERNBERG, B. *see* SCHNEIDER, H. Th.
NUTTALL, A. *see* JAMIESON, M. J.
NWOKOLO, C. U. *see* GAVEY, C. J.

O'BRYNE, S., O'CONNOR, P., GIVEN, B., CARSON, N., AFFRIME, M., KATZ, L. & FEELY, J. Chronic treatment of hypertension with dilevalol and atenolol in patients with renal insufficiency, 635P
O'CONNELL, D. *see* DRAGANIC, B.
O'CONNOR, P., ROBINSON, K., GRAHAM, I. & FEELY, J. Effect of pravastatin on lipoprotein profiles in patients with primary hypercholesterolaemia, 594P
O'CONNOR, P. *see* O'BRYNE, S.
O'DOWD, T. C. *see* VENABLES, T.
O'GRADY, J. *see* VIRGOLINI, I.
O'MALLEY, G. *see* TAYLOR, I. K.
O'NEILL, C. J. A. *see* HUGHES, J. R.
ODENDAAL, H. J. *see* SCHABORT, I.
OLESON, K. L. *see* SONNE, J.
OLIVE, G. *see* PONS, G.
OLIVER, R. M., UPWARD, J. W., DEWHURST, A. G., HONEYWELL, R., RENWICK, A. G. & WALLER, D. G. The pharmacokinetics of doxazosin in patients with hypertension and renal impairment, 417
ONG, A. C. M. *see* TOMLINSON, B.
ONON, T. *see* WILDIN, J. D.
ORME, M.L'E *see* WINSTANLEY, P. A.
OSBORNE, J. P. *see* BENNETT, P. N.
OTANI, K. *see* KONDO, T.

PAN, H. Y. *see* SINGHVI, S. M.
PAPOUCHADO, M. *see* JAMES, M. A.
PARK, B. K. *see* COLEMAN, M. D.
PARK, B. K. *see* LARKIN, J. G.
PARK, B. K. *see* RILEY, R. J.
PARK, B. K. *see* TINGLE, M. D.
PARK, B. K. *see* WINSTANLEY, P. A.
PARRISH, J. *see* TURNBULL, A. G.
PARRY-BILLINGS, M. *see* ANDERSON, I. M.
PASANEN, M. *see* BOOBIS, A. R.
PASSMORE, A. P., COPELAND, S. & JOHNSTON, G. D. The effects of ibuprofen and indomethacin on renal function in the presence and absence of frusemide in healthy volunteers on a restricted sodium diet, 311
PATAMASUCON, P. *see* WANWIMOLRUK, S.
PATEL, I. H., SONI, P. P., FUKUDA, E. K., SMITH, D. F., LEIER, C. V. & BOUDOULAS, H. The pharmacokinetics of midazolam in patients with congestive heart failure, 565
PATEL, I. H. *see* WILLS, R. J.
PATSALOS, P. N. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients, 574
PEDARRIOSSE, A. M. *see* PONS, G.
PELKONEN, O. *see* BOOBIS, A. R.
PERKINS, M. W. Failure of a nomogram to achieve target aminoglycoside concentrations, 495
PERSSON, A. *see* HASSELSTROM, J.
PETRIE, J. C. *see* JAMIESON, M. J.
PETRIE, J. C. *see* KRSKA, J.
PETRIE, J. C. *see* WEBSTER, J.
PETRING, O. U. & FLACHS, H. Inter- and intra-subject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption, 703
PFEFEN, J. P. *see* PONS, G.
PIEPER, J. A. *see* CORSI, C. M.
PIERCE, D. *see* GIRBES, A. R. J.
PIERCE, D. M. *see* ALLEN, A.
PIERCE, D. M. *see* FOWLES, S. E.
PIERCE, D. M. *see* SCHABORT, I.
PIOTROVSKII, V. K. *see* YU. MARTSEVICH, S.
PITSIU, M., AARONS, L. & ROWLAND, M. Performance of a Bayesian method using factor VII in predicting a maintenance regimen for warfarin, 646P
PITTMAN, K. A. *see* GUTTENDORF, R. J.
PLA-DELFINA, J. M. *see* GARRIGUES, T. M.
PLEUVRY, B. J. *see* WILDIN, J. D.
POLSON, R. J. *see* VLAVIANOS, P.
PONS, G., SCHOERLIN, M. P., TAM, Y. K., MORAN, C., PFEFEN, J. P., FRANCOUAD, CH., PEDARRIOSSE, A. M., CAVINIE, J. & OLIVE, G. Moclobemide excretion in human breast milk, 27
POTTER, C. E. *see* VANDENBURG, M. J.
POULEUR, H. *see* MARLOW, H. F.
POUNDER, R. E. *see* GAVEY, C. J.
PRESCOTT, L. F., MATTISON, P., MENZIES, D. G. & MANSON, L. M. The comparative effects of paracetamol and indomethacin on renal function in healthy female volunteers, 403
PRESCOTT, L. F. *see* GARRIGUES, T. M.
PRICHARD, B. N. C. *see* TOMLINSON, B.
PRIDE, N. B. *see* TAYLOR, I. K.
PRINCE, W. T. *see* FOWLES, S. E.
PUKRITTAYAKAMEE, S. *see* ROCHE, R. J.

RAE, A. P. *see* GEMMILL, J. D.
RAHMAN, A. R. *see* LANG, C. C.
RAHMAN, M. A. & BENNETT, T. The effects of propranolol or atenolol on the cardiovascular responses to central hypovolaemia in Europeans and Bengalees, 69
RANE, A. *see* HASSELSTROM, J.
RASHID, M. U. *see* BATEMAN, D. N.
RAWLES, J. *see* JAMIESON, M. J.
RAWLINS, M. D. *see* FERNER, R. E.
RAWLINS, M. D. *see* KAMALI, F.
REEF, E. *see* HAITAS, B.
REID, J. L. *see* BAINBRIDGE, A.
REID, J. L. *see* DONNELLY, R.
REID, J. L. *see* MacPHEE, G. J. A.
REITSMA, W. D. *see* GIRBES, A. R. J.
RENOULT, E. *see* KESSLER, M.
RENWICK, A. G. *see* OLIVER, R. M.
RENWICK, A. G. *see* ROBERTSON, D. R. C.
REYNOLDS, G. *see* SILKE, B.
RICHARDSON, P. D. I. *see* VENABLES, T.
RIDDELL, J. G. *see* THAM, T. C. K.
RIHOUX, J. P. *see* FINNERTY, J. P.
RILEY, M., ELBORN, J. S., KHAN, M. M., STANFORD, C. F. & NICHOLLS, D. P. Exercise limitation during treatment for angina, 593P

RILEY, M. *see* ELBORN, J. S.
RILEY, R. J., ROBERTS, P., COLEMAN, M. D., KITTERINGHAM, N. R. & PARK, B. K. A two-compartment system to investigate drug metabolite-mediated cytotoxicity *in vitro*, 625P
RITTER, J. M., BENJAMIN, N., DOKTOR, H. S., BARROW, S. E., MANT, T. G. K., SCHEY, S. & STEWART-LONG, P. Effects of a selective thromboxane receptor antagonist (GR32191B) and of glyceryl trinitrate on bleeding time in man, 431
RITTER, J. M., BENJAMIN, N., DOKTOR, H. S., BARROW, S. E., MANT, T. G. K., SCHEY, S. & STEWART-LONG, P. Effects on bleeding time of a thromboxane receptor antagonist GR32191 and of glyceryl trinitrate, 598P
ROBBINS, D. K., WEDLUND, P. J., KUHN, R., BAUMANN, R. J., LEVY, R. H. & CHANG, S. L. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine, 759
ROBERTS, C. J. C. *see* BARAKA, O. Z.
ROBERTS, M. J. *see* HACKETT, L. P.
ROBERTS, P. *see* RILEY, R. J.
ROBERTSON, D. R. C., HIGGINSON, J., MACKLIN, B. S. WALLER, D. G. & RENWICK, A. G. The influence of protein on the absorption of levodopa, 608P
ROBERTSON, D. R. C., RENWICK, A. G., WOOD, N. G., CROSS, N., MACKLIN, B. S., FLEMING, J. S., WALLER, D. G. & GEORGE, C. F. The influence of levodopa on gastric emptying in man, 47
ROBINSON, I. C. A. F. *see* BEARN, J. A.
ROBINSON, K. *see* O'CONNOR, P.
ROBSON, A. *see* NIX, A.
ROBSON, R. A., BEGG, E. J., ATKINSON, H. C., SAUNDER, D. A. & FRAMPTON, C. M. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline, 491
ROCHE, R. J., SILAMUT, K., PUKRITTAYAKAMEE, S., LOOAREESUWAN, S., MOLUNTO, P., BOONAMRUNG, S. & WHITE, N. J. Quinine induces reversible high-tone hearing loss, 780
RODGERS, A. V. *see* COPPACK, S. W.
ROLLS, L. J. *see* MINTON, N. A.
ROSENBUSCH, G. *see* HOPMAN, W. P. M.
ROSS, C. E. *see* TOON, S.
ROUSSEAU, M. F. *see* MARLOW, H. F.
ROWE, P. R. *see* HOWES, L. G.
ROWLAND, M. *see* BERNAREGGI, A.
ROWLAND, M. *see* PITSIU, M.
ROY-CHAUDHURY, P. *see* WEBSTER, J.
RUMIANTSEV, D. O. *see* YU. MARTSEVICH, S.
RUTTER, N. *see* CARTWRIGHT, R. G.

SALAKO, L. A. *see* WINSTANLEY, P. A.
SALEH, S., JOHNSTON, A. & TURNER, P. Absolute bioavailability of medifoxamine in healthy human volunteers, 622P
SALMONSON, T., DANIELSON, B. G. & WIKSTROM, B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects, 709
SALVADORI, C. *see* SINI, R.
SAMIGUN, MULYONO & SANTOSO, B. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators, 570
SANTOSO, B. *see* SAMIGUN
SANZ, E. *see* ALVAN, G.
SAOTOME, T. *see* ECHIZEN, H.
SASSARD, J. *see* BENZONI, D.
SAUNDER, D. A. *see* ROBSON, R. A.
SAWE, J. *see* HASSELSTROM, J.
SCHABORT, I., ODENDAAL, H. J. & PIERCE, D. M. The pharmacokinetics of oral indoramin during pregnancy, 397
SCHELLENS, J. H. M., VAN DER WART, J. G. F. & BREIMER, D. D. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects, 665
SCHEY, S. *see* RITTER, J. M.
SCHNEIDER, H. TH., NEURNBERG, B., DIETZEL, K. & BRUNE, K. Biliary elimination of non-steroidal anti-inflammatory drugs in patients, 127
SCHOEMAKER, H. C. *see* KROON, C.
SCHOEMAKER, H. C. *see* SOONS, P. A.
SCHOEMAKER, H. C. *see* VAN HALL, M.
SCHOEMAN, H. S. *see* MEYER, E. C.
SCHOEMAN, H. S. *see* SNYMAN, J. R.
SCHOERLIN, M. P. *see* PONS, G.
SCHOORS, D. F. & DUPONT, A. G. Lithium does not reduce the natriuretic response to dopamine in man, 581
SCHOORS, D. F., VERCRUYSSE, I., MUSCH, G., MASSART, D. L. & DUPONT, A. G. Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers, 497
SCULLY, N. L. *see* THOMAS, M.
SEARLE, G. F. *see* STURGESS, I.
SEGURA, J. *see* BOOBIS, A. R.
SEGURA, J. *see* SESARDIC, D.
SENNESAEL, J. *see* SLOVICK, D.
SERREE, J. M. P. *see* TH. VEERING, B.
SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. & DAVIES, D. S. Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man, 651
SESARDIC, D. *see* BOOBIS, A. R.
SETTIN, A. *see* VLAVIANOS, P.
SHARMA, S. *see* SILKE, B.
SHARPLEY, A. L., FERNANDO, A. & COWEN, P. J. The effect of nifedipine on the sleep EEG in healthy volunteers, 629P
SHAWKET, S., DICKERSON, J. E. C., HAZLEMAN, B. & BROWN, M. J. Double-blind comparison of CGRP and prostacyclin in primary Raynaud's phenomenon: prolonged hand rewarming after CGRP, 595
SHERIDAN, D. J. *see* THOMAS, P.
SHUSTER, S. *see* HUMPHREYS, F.
SILAMUT, K. *see* ROCHE, R. J.
SILKE, B. *see* GUY, S.
SILKE, B., VERMA, S. P. & TAYLOR, S. H. Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-Doppler device, 741
SILKE, B., VERMA, S. P., ZEZULKA, A. V., SHARMA, S., REYNOLDS, G., JACKSON, N. C., GUY, S. &

TAYLOR, S. G. Haemodynamic and radionuclide effects of amlodipine in coronary artery disease, 437
SILKE, B., ZEZULKA, A. V., VERMA, S. P., THAM, T. C. K. & TAYLOR, S. H. Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function, 749
SIMOOYA, O. *see* WINSTANLEY, P. A.
SINGHVI, S. M., PAN, H. Y., MORRISON, R. A. & WILLAD, D. A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects, 239
SINI, R., MORIN, D., SALVADORI, C. & TILLEMENT, J. P. Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure, 9
SINZINGER, H. *see* VIRGOLINI, I.
SKANBERG, I. *see* ANDERSON, T.
SLASTNIKOVA, I. D. *see* YU. MARTSEVICH, S.
SLATER, N. D. *see* MACLEAN, D.
SLOVICK, D., ALI, A., FOURNIER, A., SENNESAEL, J., SWENY, P., DESCHE, P. & VANDENBURG, M. Pharmacokinetics of perindopril and perindoprilat in hypertensive patients with renal impairment, 647P
SMIT, A. J. *see* GIRBES, A. R. J.
SMITH, A. *see* DRAGANIC, B.
SMITH, D. F. *see* PATEL, I. H.
SMITH, F. W. *see* JAMIESON, M. J.
SMITH, J. T. L. *see* GAVEY, C. J.
SMITH, K. J. *see* MINTON, N. A.
SMITH, L. *see* VANDENBURG, M. J.
SMITH, M. *see* KRSKA, J.
SMITH, S. *see* JAMIESON, M. J.
SMITH, S. E. *see* YEANG, Y.
SMY, J. R. *see* JAVLE, H.
SMYTH, R. L. *see* CUTHBERT, A. W.
SNOW, H. M. *see* MARLOW, H. F.
SNYMAN, J. R., MEYER, E. C. & SCHOEMAN, H. S. Cimetidine as modulator of the cell-mediated immune response *in vivo* using the tuberculin skin test as parameter, 257
SOARES DE MOURA, R. & JAZBIK, W. Effect of cromakalim on the human saphenous vein, 621P
SOHNIUS, U. *see* HIFT, R.
SOMMERS, DE K. *see* MEYER, E. C.
SOMOGYI, A., HEWSON, D., MUIRHEAD, M. & BOCHNER, F. Amiloride disposition in geriatric patients: importance of renal function, 1
SONI, P. P. *see* PATEL, I. H.
SONI, P. P. *see* WILLS, R. J.
SONNE, J., DOSSING, M., LOFT, S., OLESON, K. L., VOLMER-LARSEN, A., VICTOR, M. A., HAMBERG, O. & THYSSEN, H. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol, 33
SOONS, P. A., UCHIDA, E., DE BOER, A., SCHOEMAKER, H. C., BREIMER, D. D. & COHEN, A. F. Effects of exercise and i.v. propanolol on liver blood flow in healthy subjects, estimated with a continuous infusion of indocyanine green, 642P
SOUVERIJN, J. H. M. *see* TH. VEERING, B.
SPIERDIJK, JOH. *see* TH. VEERING, B.
SPIERS, C. J., MURRAY, S., DAVIES, D. S., BIOLA MABADEJE, A. F. & BOOBIS, A. R. Debrisoquine oxidation phenotype and susceptibility to lung cancer, 101
STACPOOLE, P. W. *see* CURRY, S. H.
STANDRING, R. *see* GIRBES, A. R. J.
STANFORD, C. F. *see* ELBORN, J. S.
STANFORD, C. F. *see* RILEY, M.
STANIFORTH, D. H. *see* GILL, T. S.
STEWART-LONG, P. *see* RITTER, J. M.
STOTT, N. C. H. *see* VENABLES, T.
STRUTHERS, A. D. *see* LANG, C. C.
STURGESS, I. & SEARLE, G. F. The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality, 369
SVENSSON, J. O. *see* HASSELSTROM, J.
SWENY, P. *see* SLOVICK, D.
SWIFT, C. G. *see* ARNOLD, J. D.
SZABADI, E. *see* BAKES, A.
SZABADI, E. *see* LONGMORE, J.

TAGA, J. *see* HORAI, Y.
TAKEBE, K. *see* BABA, T.
TAM, Y. K. *see* PONS, G.
TATTERSALL, R. B. *see* KERR, D.
TAYLOR, A. *see* BENNETT, P. N.
TAYLOR, G. W. *see* TAYLOR, I. K.
TAYLOR, I. K., O'MALLEY, G., MURRAY, S., TAYLOR, G. W., FULLER, R. W., PRIDE, N. B. & DOLLERY, C. T. Kinetics of urinary *N*-MIAA after infusion of histamine in normal volunteers, 612P
TAYLOR, S. H. *see* SILKE, B.
TH. VEERING, B., BURM, A. G. L., SOUVERIJN, J. H. M., SERREE, J. M. P. & SPIERDIJK, JOH. The effect of age on serum concentrations of albumin and α_1-acid glycoprotein, 201
THAM, T. C. K., LENNON, P. & RIDDELL, J. G. The effects of single oral doses of chlorpromazine, amitriptyline, mianserin, salbutamol and propranolol on tremor, sedation, heart rate, and blood pressure in man, 630P
THAM, T. C. K. *see* SILKE, B.
THIRKETTLE, C. *see* HENRY, D.
THOMAS, M., KENSINGTON, J. E., KEERY, R. J., CHARTER, M. K., SCULLY, N. L. & LUMLEY, P. An initial study with intravenous GR32191, a thromboxane receptor blocking agent, in healthy volunteers, 597P
THOMAS, P., DIXON, M. S., WINTERTON, S. J. & SHERIDAN, D. J. Acute haemodynamic effects of cromakalim in patients with angina pectoris, 325
THOW, J. C. *see* FOWLES, S. E.
THUILLEZ, C., BELLISSANT, E. & GIUDICELLI, J. F. Pinacidil dilates both arterioles and large conductance vessels in healthy volunteers, 616P
THYSSEN, H. *see* SONNE, J.
TILLEMENT, J. P. *see* SINI, R.
TIMERICK, S. J. B. *see* VENABLES, T.
TIMONEDA, F. L. *see* MUNOZ, J. J.
TINGLE, M. D., COLEMAN, M. D. & PARK, B. K. Investigation of dapsone-induced methaemoglobinaemia *in vitro*: effect of enzyme inhibition, 624P

TINGLE, M. D. & PARK, B. K. Metabolism of ciamexon by human liver microsomes: an investigation into the formation of stable, chemically reactive and cytotoxic metabolites, 549
TJANDRA, Y. I. *see* BARENDREGT, J. N. M.
TOMIYAMA, T. *see* BABA, T.
TOMLINSON, B., ONG, A. C. M., GRAHAM, B. R. & PRICHARD, B. N. C. Effects of noradrenaline infusion on cardiac output and systolic time intervals derived from electrical bioimpedance cardiography, 639P
TONNEL, A. B. *see* MARQUETTE, C. H.
TOON, S., ROSS, C. E., GOKAL, R. & ROWLAND, M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole, 221
TRECHOT, P. *see* KESSLER, M.
TREGASKIS, B. F. *see* LIPWORTH, B. J.
TRUMAN, C. A. *see* BARAKA, O. Z.
TSICOPOULOS, A. *see* MARQUETTE, C. H.
TURNBULL, A. G., LIS, Y., PARRISH, J. & WALKER, S. R. The impact of the clinical trial exemption scheme on clinical development in the UK, 616P
TURNER, P. *see* SALEH, S.

UCHIDA, E. *see* SOONS, P. A.
UEMATSU, T. *see* MATSUNO, H.
UFFMAN, J. *see* WILKENS, J. H.
UPWARD, J. W. *see* ALLEN, A.
UPWARD, J. W. *see* OLIVER, R. M.

VAAG, A. *see* MOLLER, B.
VAN DER HOEVEN, J. G. *see* BARENDREGT, J. N. M.
VAN DER MEER, F. J. M. *see* KROON, C.
VAN DER WART, J. G. F. *see* SCHELLENS, J. H. M.
VAN HALL, M., VAN HARTEN, J., SCHOEMAKER, H. C., BREIMER, D. D. & COHEN, A. F. A computerised pump system for the administration of individualised infusions to human subjects. A tool for the study of rate-dependent effects, 648P
VAN HARTEN, J. *see* VAN HALL, M.
VAN OENE, J. C. *see* BARENDREGT, J. N. M.
VAN PEER, A. *see* BARENDREGT, J. N. M.
VAN VLIET, A. *see* DE BOER, A.
VANDENBURG, M. J., WIGHT, L. J. & POTTER, C. E. Microbiological effectiveness of cefuroxime axetil (CAE) in urinary tract infections presenting to the general practitioner, 636P
VANDENBURG, M. *see* SLOVICK, D.
VENABLES, T., AKHTAR, W., CAMPBELL, L. M., FOX, Y., GROOM, P., MANSY, S., NAQVI, N., O'DOWD, T. C., RICHARDSON, P. D. I., STOTT, N. C. H., TIMECK, S. J. B., WARD, D. E. & WILKINSON, R. Low dose felodipine with low dose metoprolol as once daily antihypertensive therapy, 628P
VERBEECK, R. K., LOEWEN, G. R., MACDONALD, J. I. & HERMAN, R. J. The effect of multiple dosage on the kinetics of glucuronidation and sulphation of diflunisal in man, 381
VERCRUYSSE, I. *see* SCHOORS, D. F.
VERMA, S. P. *see* SILKE, B.
VICTOR, M. A. *see* SONNE, J.
VILLEN, T. *see* ALVAN, G.
VIRGOLINI, I., ANGELBERGER, P., CH. MULLER, O'GRADY, J. & SINZINGER, H. 99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) *in vitro*, 207
VLAVIANOS, P., POLSON, R. J., SETTIN, A., GLOVER, J., WESTABY, D. & WILLIWMAS, R. Haemodynamic and pharmacokinetic study of intravenous fenoldopam in patients with hepatic cirrhosis, 19
VOLLMER-LARSEN, A. *see* SONNE, J.
VORNIG, H. *see* MARQUETTE, C. H.
VYGODIN, V. A. *see* YU. MARTSEVICH, S.
VANDENBURG, M. J., MACKAY, E. M., LAHER, M. S., DONOHOE, J., DOYLE, G. D., KELLY, J. G., GLOVER, D. R. & SMITH, L. The chronic pharmacokinetics of dilevalol in renal impairment, 615P

WAHBHA, M. M. A. E., WILSON, J. & HAINSWORTH, R. Cardiovascular responses to upright tilting in hypertensive patients, with and without renal impairment and before and following nisoldipine treatment, 733
WALKER, O. *see* WINSTANLEY, P. A.
WALKER, S. R. *see* TURNBULL, A. G.
WALLER, D. G. *see* OLIVER, R. M.
WALLER, D. G. *see* ROBERTSON, D. R. C.
WALLWORK, J. *see* CUTHBERT, A. W.
WANWIMOLRUK, S., PATAMASUCON, P. & LEE, E. J. D. Evidence for the polymorphic oxidation of debrisoquine in the Thai population, 244
WARD, D. E. *see* VENABLES, T.
WARD, S. A. *see* HELSBY, N. A.
WARDELWORTH, A. G. *see* JAMES, M. A.
WEBB, A. J. *see* AL-AZAWIE, D. M.
WEBB, D. J. *see* BENJAMIN, N.
WEBER, M. A. *see* GRIFFITHS, A. N.
WEBSTER, J., PETRIE, J. C., JEFFERS, T. A., ROY-CHAUDHURY, P., CRICHTON, W., WITTE, K. & JAMIESON, M. Efficacy and tolerability of a sustained release formulation of nicardipine in hypertension assessed by clinic and home blood pressure recordings, 587P
WEBSTER, J. *see* JAMIESON, M. J.
WEDLUND, P. J. *see* GUTTENDORF, R. J.
WEDLUND, P. J. *see* ROBBINS, D. K.
WESTABY, D. *see* VLAVIANOS, P.
WHITE, N. J. *see* ROCHE, R. J.
WHYTE, I. *see* DRAGANIC, B.
WIGHT, L. J. *see* VANDENBURG, M. J.
WIKSTROM, B. *see* SALMONSON, T.
WILDIN, J. D., PLEUVRY, B. J., MAWER, G. E., ONON, T. & MILLINGTON, L. Respiratory and sedative effects of clobazam and clonazepam in volunteers, 169
WILKENS, J. H., WILKENS, H., UFFMAN, J., BOVERS, J., FABEL, H. & FROLICH, J. C. Effects of a PAF-antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma, 85
WILKENS, H. *see* WILKENS, J. H.
WILKINSON, R. *see* VENABLES, T.
WILLARD, D. A. *see* SINGHVI, S. M.
WILLIAMS, A. *see* KRSKA, J.

WILLIAMS, H. *see* ANDERSON, I. M.
WILLIWMAS, R. *see* VLAVIANOS, P.
WILLS, R. J., KHOO, K. C., SONI, P. P. & PATEL, I. H. Increased volume of distribution prolongs midazolam half-life, 269
WILSON, J. *see* WAHBHA, M. M. A. E.
WILSON, R. E. A. *see* JOHNSTON, G. D.
WINGSTRAND, K. *see* BLYCHERT, E.
WINSTANLEY, P. A., COLEMAN, J. W., MAGGS, J. L., BRECKENRIDGE, A. M. & PARK, B. K. The toxicity of amodiaquine and its principal metabolites towards mononuclear leucocytes and granulocyte-monocyte colony forming units, 479
WINSTANLEY, P. A., SIMOOYA, O., KOFI-EKUE, J. M., WALKER, O., SALAKO, L. A., EDWARDS, G., ORME, M. L'E & BRECKENRIDGE, A. M. The disposition of amodiaquine in Zambians and Nigerians with malaria, 695
WINTERTON, S. J. *see* THOMAS, P.
WITTE, K. *see* WEBSTER, J.
WOJNAR-HORTON, R. E. *see* HACKETT, L. P.
WOLF, G. K. *see* BELZ, G. G.
WONG, C. K. Y. *see* BARIN, E. S.
WOOD, N. G. *see* ROBERTSON, D. R. C.
WOODHOUSE, K. W. *see* GEORGE, G.
WRIGHT, P. M. C., CARABINE, U. A., MCCLUNE, S., MOORE, J. & FEE, J. P. H. An α_2-adrenoceptor agonist as preanaesthetic medication: preliminary analysis, 600P
WYNNE, H. A. *see* GEORGE, G.

YANG, J. *see* DUNDEE, J. W.
YEANG, Y. & SMITH, S. E. Effects of anticholinergic agents on sinus arrhythmia in healthy subjects, 647P
YU, Y. L. *see* KUMANA, C. R.
YU. MARTSEVICH, S., METELITSA, V. I., RUMIANTSEV, D. O., PIOTROVSKII, V. K., SLASTNIKOVA, I. D., EGOROV, L. V. & VYGODIN, V. A. Development of tolerance to nifedipine in patients with stable angina pectoris, 339

ZEZULKA, A. V. *see* SILKE, B.
ZUSSMAN, B. D. *see* ALLEN, A.

SUBJECT INDEX

P = proceedings

α_1-acid glycoprotein, 9, 201, 423
α_1-adrenoceptor antagonist, 359
α_2-adrenoceptor antagonist, 138, 600P
Absorption, 39, 149P, 239, 703
ACE inhibitor, 586P, 611P
Acenocoumarol, 643P
Acetaminophen, 403
Acetylation, 503
Acetylator status, 570
Acetylsalicylic acid, 305
Acupressure, 644P
Acupuncture, 601P
Adverse renal effects, 403
Afterload, 366
Age, 179, 603P, 606P, 637P
Airway responsiveness, 725
Airways, 613P
Albumin, 201
Alcohol, 139P
Aldosterone release, 606P
Aluminium sucralfate, 391
Amiloride, 1, 227, 235
Amitriptyline, 630P
Amlodipine, 437
Amodiaquine, 479, 695
Angina, 333
Angina pectoris, 339
Angiotensin II, 143P, 144P
Angiotensin converting enzyme inhibitor, 140P, 363
Anipamil, 627P
Anistreplase, 597P
Anorexic, 604P
Anticholinergic agents, 647P
Antidepressant, 27
Antiemesis, 601P
Antiemetic, 644P
Anti-herpes drug, 620P
Antihypertensive effect, 39
Antipyrine, 261
Anxiety, 590P
Anxiolytic drugs, 141P
Arthroscopy, 600P
Aspirin, 120
Aspirin-sensitive asthma, 525
Asthma, 151P
Asthma, exercise induced, 85
Atenolol, 69, 265, 455, 635P, 725, 741
Atherosclerosis, 638P
Atrial fibrillation, 136
Atrial natriuretic factor, 606P
Atropine, 603P
Autonomic blockers, 254
Autonomic failure, 154P

β-adrenoceptor, 265
β-adrenoceptor agonist, 355
β-adrenoceptor blockade, 154P, 685
β-adrenoceptor blocking agents, 725
β-adrenoceptor response, 613P
β_1-adrenoceptor partial agonist, 631P
β_2-adrenoceptor agonist, 321, 632P
β_2-adrenoceptor responses, 137P
β-thromboglobulin, 85
Benzodiazepines, 61, 593
Biguanide antimalarials, 623P
Bile acids, 541
Biliary elimination, 127
Bioavailability, 39, 239, 289, 486, 541, 557, 574, 620P, 622P
Bleeding time, 431, 599P
Blood pressure, 61
Bradykinin, 140P, 363
Breast milk, 27, 277, 777
Breath tests, 355
BRL 43694, 619P
Bronchial hyperreactivity, 79
Bronchogenic polymorphism, 101

CCK receptor antagonists, 770
Cadralazine, 503
Calcitonin gene related peptide, 595P
Calcium channel antagonist, 627P
Carbamazepine, 116, 137P, 574, 759, 763
Carbamazepine-diol, 763
Carbamazepine-epoxide, 763
Carbidopa, 147P
Cardiac glycosides, 93
Cardiac performance, 608P
Cardiac power output, 608P
Cardiovascular reflex, 733
Cardiovascular responses, 69
Carvedilol, 486
Cefadroxil, 602P
Cefuroxine axetil, 636P
Cephalosporins, 601P
Cetirizine, 79
Chewable carbamazepine, 574
Chlorproguanil, 623P
Chlorpromazine, 630P
Chloroquine, 149P, 479
Cholecystokinin, 55, 770
Cholinergic function, 633P
Ciamexon, 549
Cimetidine, 257, 610P, 643P
Ciprofloxacin, 491
Cirrhosis, 9, 19
Clinical development, 616P
Clinical trial exemption, 616P
Clobazam, 169, 763
Clofibrate, 473
Clonazepam, 169
Clonidine, 138P, 596P, 600P
Combination therapy, 455
Compliance, 465
Computerized pump, 648P
Concentrations, 777

Congestive heart failure, 565
Counter-regulation, 685
Cromakalim, 325, 617P, 621P
Cyclopenthiazide, 586P
Cyclosporin, 370, 541
Cystic fibrosis, 227, 235
Cytochrome P-450, 491, 665
Cytochrome P4501A, 603P
Cytochrome $P4501A_2$, 651
Cytotoxic, 549
Cytotoxicity, 479, 625P

Dapsone, 624P, 625P
Deafness, 780
Debrisoquine, 101, 111, 244
Dextromethorphan, 373
Diabetes, 638P
Diazepam, 123, 593
Dichloroacetic acid, 622P
Diclofenac, 127, 600P
Diflunisal, 381
Digoxin, 136, 486
Dilevalol, 281, 615P, 635P, 725
Dipeptide renin inhibitor, 614P
Discharge information, 142P
Disopyramide, 423, 633P
Disposition, 1
Diuretic effect, 215
Diuretic efficiency, 215
Dopamine, 413
Dopamine receptors, 19
Dopaminergic D_2-receptor agonist, 619P
Dosage forms, 215
Dosage history, 187
Dose-effect relationship, 299
Dose-response effects, 437, 749
Doxazosin, 417
Drug coadministration, 373
Drug interactions, 261, 763
Drug metabolism, 261
Duodenal ulcer patients, 465

EEG, 289
Echo-Doppler, 741
Elderly, 9, 61, 137P, 333
Electrical bioimpedance cardiography, 639P
Electrophysiology, 359
Elimination half-life, 770
Enalapril, 140P, 611P, 641P, 766
Enalaprilat, 614P, 766
Enalkrein, 614P
Enzyme, 651
Enzyme induction, 637P, 643P
Enzyme inhibition, 624P
Epanolol, 333
Epileptic patients, 574
Epithelial cell culture, 235
Epithelial ion transport, 227
Epoxide hydrolase, 759
Erythropoietin, 709
Ethnic differences, 254, 634P
Ethnicity, 69
Exercise tests, 339

Famicicrovir, 620P
Felodipine, 39, 146P, 628P
Fenoldopam, 19, 413
Flare, 195
Flosequinan, 519
Fluconazole, 221
Flumazenil, 593
Flushing, 120
Food, 620P
Foot strike, 179
Forearm, 774
Formoterol, 321
Formulation, 137P
Formulations, 39
Frusemide, 215, 311
Furafylline, 651
Furanoid acid, 153P

Gait, 147P
Gallbladder, 55
Gastric emptying, 47, 603P, 703
Gastrointestinal absorption, 391
Gastrointestinal motility, 355
Gastrointestinal prokinetic drug, 618P
Genetic polymorphism, 101, 244, 248, 299, 633P
Geriatric patients, 1
Glibenclamide, 673
Glomerular filtration, 403
Glucuronidation, 33, 381
Glycerol i.v., 347
Glyceryl trinitrate, 431, 598P
Gold, 777
GR 32191, 597P, 598P, 599P
Granisetron, 619P

H^+/K^+ ATPase inhibitor, 609P
H_1-receptor antagonist, 79, 607P
HMG-CoA reductase inhibitor, 239
Haemodialysis, 221, 715
Haemodynamic, 359
Haemodynamics, 437, 617P, 749
Haemolysis, 347
Haemostasis, 431
Half-life, 269
Haloperidol, 187
Healthy volunteers, 465
Heart failure, 366, 447, 511, 519, 641P
Heart rate, 254
Heparin, 599P
Histamine, 79, 612P
Hospital records, 143P
Hospital drug formularies, 630P
5-HT_3 receptor antagonist, 619P
Human hepatic binding protein (HBP), 207
Human milk, 123, 777
Human monooxygenase activity, 651
Human serum albumin, 9
Hydralazine, 366
Hydrazino metabolite, 503
Hydrogel discs, 533
6-hydroxyindoramin, 397
5-hydroxytryptamine, 141P
Hypertension, 146P, 417, 455, 586P, 611P, 614P, 628P, 635P, 647P, 733

Hypocholesterolaemic agent, 239
Hypoglycaemia, 685
Hypoglycaemic awareness, 685

Ibuprofen, 127, 311
Idazoxan, 138P
Immune modulation, 257
In vitro evaluation, 347
Indocyanine green, 642P
Indomethacin, 127, 195, 311, 403
Indoramin, 397
Induction, 603P
Infant plasma, 777
Inhibition, 299, 525
Inhibition of PAH acetylation, 403
Inotrope, 511
Interaction, 486, 491, 628P, 643P
Intermittent administration, 465
Intragastric acidity, 473
Intravenous, 709
Irritable bowel syndrome, 355
Ischaemic heart disease, 741, 749
Isoniazid, 570

Japanese, 111
Judgement analysis, 155P

K^+ channel activator, 616P, 617P, 621P
Ketanserin, 715
Ketoconazole, 645P, 783
Kidney function, 1
Kinetics, 557
Kininase II, 774

Labetalol, 33
Lactate, 150P, 636P
Leishmaniasis, 645P
Leucocytes, 93
Levodopa, 47, 147P, 179, 608P
Lipoproteins, 281
Lipoxygenase, 152P
Liquids, 703
Lithium, 413
Liver blood flow, 642P
Liver cirrhosis, 289, 766
Liver microsomes, 549
Lomefloxacin, 491
Loxiglumide, 770
Loperamide, 55
Lormetazepam, 156P
Lower body negative pressure, 69, 144P
Lung cancer, 101

Magnesium deficiency, 136
Magnetic resonance imaging, 157
Magnetic resonance spectroscopy, 157
Malaria, 149P, 695
Man, 774
Medifoxamine, 622P
Mefloquine, 149P
Meglumine antimonate, 623P
Mephenytoin, 373, 665
Metabolic effects, 586P
Metabolism, 157, 239
Metabolite kinetics, 759
Metabolites, 549
Methacholine, 79, 321
Methaemoglobinaemia, 624P, 625P
Methylphenytoin and phenobarbitone hydroxylation, 665
Metoclopramide, 606P
Metoprolol, 111, 628P
Mianserin, 630P
Midazolam, 269, 565
Moclobemide, 27
Mono-unsaturated metabolites, 116
Monoamine oxidase inhibitor, 27
Monocytes, 637P
Mononuclear, 93
Monoxidine, 596P
Morphine, 289
Multiple dose pharmacokinetics, 381
Multiple plasma peaks, 47
Myocardial infarction, 597P

N-desmethyldiazepam, 123
N-methylimidazole acetic acid, 612P
$Na^+ - K^+$ ATPase, 93
Nadolol, 265
Natriuresis, 403, 413
Nedocromil sodium, 525
Neoglycoalbumin (NGA), 207
Neonate, 123, 423
Nicardipine, 145P, 497
Niceritrol, 120
Nifedipine, 339, 629P
Nisoldipine, 366, 733
Nitrendipine, 455
Nitroglycerine, 741
Noberastine, 607P
Non-allergic, 725
Non-insulin dependent diabetes, 673
Non-steroidal anti-inflammatory drugs, 606P
Nuclear magnetic resonance, 157P

Octreotide, 154P
Oestrogen receptor, 604P
Omeprazole, 465, 557, 610P
Opiate receptor agonist, 55
Orthostasis, 61
Overdose, 605P
Oxazepam, 33, 123
Oxcarbazepine, 643P
Oxidation, 244
Oxidation phenotype, 101, 244
Oxidation polymorphism, 111

P6 acupuncture, 644P
PGE-MUM, 305
Paracetamol, 47, 261, 305, 403, 703
Parietal cells, 610P
Parkinson's disease, 147P
Parkinsonism, 179
Patient acceptability, 142P
Patient medication, 143P
Patients, 565
Penciclovir, 620P
Pentobarbitone, 643P

Pepsinogen A, 465
Pepsinogen C, 465
Peptic ulcer, 606P
Perindopril, 647P
Perindoprilat, 647P
Period interaction, 626P
Pharmacogenetics, 244
Pharmacodynamics, 33, 145P, 157, 497, 673
Pharmacokinetics, 33, 127, 145P, 148P, 149P, 221, 239, 248, 269, 289, 333, 370, 397, 417, 497, 503, 565, 574, 597P, 612P, 615P, 617P, 622P, 673, 709, 715, 766
Phenytoin, 116, 665
Phosphodiesterase inhibitor, 369
Pilocarpine, 150P, 636P
Pinacidil, 616P
Plasma concentration, 339, 391
Plasma gastrin, 473
Plasma protein binding, 381
Platelet activating factor antagonist, 85
Platelet aggregation, 85
Platelet factor 4, 85
Platelets, 525
Polymorphic metabolism, 373
Polymorphism, 665
Polymorphonuclear, 93
Porphyria, 273
Portal hypertension, 19
Postpartum, 423
Pravastatin sodium, 239
Preanaesthetic medication, 600P
Pregnancy, 397, 423
Preload, 366
Premature infants, 533
Pro-drug, 620P
Proguanil, 623P
Propranolol, 33, 69, 261, 497, 630P, 642P
Prostacyclin, 638P
Prostaglandins, 403
Protein, 608P
Protein binding, 9, 153P, 423, 634P
Proton pump inhibitor, 557
Psychomotor function, 139P
Psychomotor tests, 169
Puerperal women, 604P
Pupillary light reflex, 590P

Quality of life, 155P
Quinidine, 248, 299
Quinine, 780

Radioimmunoassay, 618P
Radionuclide scintigraphy, 703
Ramipril, 628P
Randomised double-blind clinical trial, 347
Rate-dependent effects, 648P
Reduced haloperidol, 187
Renal clearance, 1
Renal failure, 9, 417, 733
Renal function, impaired, 627P
Renal haemodynamics, 417
Renal impairment, 145P, 221, 615P, 647P
Renal insufficiency, 635P, 715
Renal plasma flow, 403
Renal prostaglandin E_2, 305
Renin, 413
Renzapride, 618P
Repeated dosing, 557
Rheumatoid arthritis, 152P
Rolipram, 369
Ropinirole, 619P

Salbutamol, 137P, 151P, 630P
Salivary flow, 603P
Salmeterol, 630P
Scalp hair, 187
Semi-solids, 703
Sequence effects, 626P
Sinus arrhythmia, 647P
SK & F 95601, 609P
Skin test, 257
Sleep, 138P
Sleep EEG, 629P
Sodium aurothiomalate, 777
Sodium restriction, 311
Sodium stibogluconate, 623P
Sodium transport, 235
Sotalol, 277
Sparteine, 111, 248
Sparteine oxidation, 299
Spiramycin, 370
Splanchnic haemodynamics, 25
Steady-state, 759
Streptokinase, 597P
Stroke, 347
Stroke volume, 640P
Subcutaneous, 709
Submaximal exercise, 519
Substance P, 774
Substituted benzimidazole, 557
Sulindac, 140P, 363
Sulphation, 381
Sweat, 150P, 636P
Sweat glands, 227, 235
Systemic haemodynamics, 19
Systolic time intervals, 447, 639P

Teicoplanin, 612P
Temazepam, 61, 123
Terbutaline, 321
Thai, 244
Theophylline, 265, 491, 533, 570, 605P
Therapeutic drug monitoring, 133, 278
Thromboxane receptor antagonist, 431, 598P, 599P
Thromboxane receptor blocking agent, 597P
Tianeptine, 9
Tissue characterization, 157
Tolbutamide, 638P
Tolerance, 339
Toxicity, 623P, 780
Transdermal delivery, 533
Treatment, 626P
Trimipramine, 148P
Two-period crossover studies, 626P
Typhoid vaccine, 154P
Tyramine, 143P

UK-52,046, 749
Uraemia, 153P
Urinary elimination, 391
Urinary tract infection, 636P
Urticaria, 195

Valproic acid, 116, 759
Vancomycin, 273
Variability, 703
Vasodilator, 325
Ventilatory response to CO_2, 169

Warfarin, 646P
Water excretion, 403
Weal reactions, 195

Xamoterol, 447, 511, 631P, 641P